Psychedelics Therapy

Colombia's President Admits To Drinking Ayahuasca (UPDATED)
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
Sponsored
Jamaica-Based Kaya Group Partners With Silo Wellness, Announce Share Exchange And Psychedelic Wellness Retreats
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
Sponsored
Jamaica-Based Kaya Group Partners With Silo Wellness, Announce Share Exchange And Psychedelic Wellness Retreats
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
NIDA Partners With The National Institute Of Mental Health To Study Psychedelics Potential

Psychedelics Therapy Recent News

Join Renowned Psychiatrists In This Free Webinar On Psychedelic-Assisted Therapy
Australia has announced that it will become the first country in the world to reschedule the medical use of MDMA and Psilocybin, two key ingredients in psychedelic drugs.
Studying Psychedelics As Medicine: UK University Offers Postgrad Course On Clinical Use
The University of Exeter is launching a new postgraduate program on psychedelics, called "Psychedelics: Mind, Medicine, and Culture." The program aims to train therapists, mental health advocates, and healthcare workers on how to safely work with psilocybin, LSD, MDMA, and other psychoactive drugs in therapeutic work.
Psychedelics Producer Lucy Scientific Discovery Partners With Pramantha Group For Funding: What's Next?
Early-stage psychedelics manufacturing company Lucy Scientific Discovery Inc.
People Science Raises $5.3M For Evolution Of Therapeutic Alternatives: Psychedelics & Cannabis
Private biopharma company People Science raised $5.3 million in its second seed round, which was led by Acre Venture Partners and followed by Bluestein Ventures, THIA Ventures and FORM Life Ventures.
Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good Manufacturing Practices (GMP) facility in January 2023.
California's Psychedelics Decrim Bill Back In The Game, Led By State Sen. Scott Wiener
A new bill decriminalizing possession and personal use of certain psychedelics backed by mental health professionals and veterans and led by Sen. Scott Wiener (D-SF) was introduced in California’s Senate on Monday.
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed:
Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S.
Psychedelic Therapy Boosted By 3D Movement Data? This Company Is Aiming To Patent The Combination
Canadian magic mushrooms and truffles producer Red Light Holland Corp.
Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
Biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed four new U.S. Patent Cooperation Treaty (PCT) applications aiming to convert five provisional patent applications. 
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
The Beckley Foundation and its founder and long-time psychedelics researcher Amanda Feilding announced a new research program involving a pioneering study with King's College London and UCL on the effects of full dose LSD as well as a breakthrough study with the University of Bas
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.
Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update
Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.
Elon Musk Joins Twitter Conversation About Psychedelics: A Debate On Empathy
Elon Musk continues touting the benefits of psychedelics, from his live interview at CodeCon2021 to his most recent tweets endorsing those
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.
COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights
Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.
Psychedelics Company Launches New Supplements Line, Joins Global Wellness Market
Mental health company Revitalist Lifestyle and Wellness Ltd.
New York Update: Will Psychedelics Achieve Legal Status In 2023? Details On A Newly Amended Bill
Democratic Assemblymember Linda Rosenthal's 2021 psychedelics bill was intended to delist psilocybin and psilocin as Schedule I substances. Nonetheless, on October 3, 2022, that same
Can Ketamine Treat Alcohol Addiction? This Is How Therapy Actually Functions
(Part two of a four-part series, see part one here)
Can Ketamine Treat Alcohol Addiction? Clinics & Hospitals In Europe And North America Are Already Doing It
(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform.
Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage
Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics
Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.
First International Psilocybin Supply Agreement For Optimi Health: Here Are The Details
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that it has entered into its first international psi
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved